Please check your internet connection and try again.
# Clobazam (Oral)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) and other seizure types.
## Primary Indications
* Adjunctive therapy for seizures in patients with Lennox-Gastaut syndrome (LGS).
* Adjunctive therapy for other seizure types, including absence, myoclonic, and atonic seizures.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Initiate at 5 mg twice daily.
* Titrate by 5-10 mg per day every 7 days to a target dose of 10 mg twice daily.
* Maximum dose: 20 mg twice daily.
* **Other Seizure Types:**
* Initiate at 5 mg twice daily.
* Titrate by 5-10 mg per day every 7 days to a target dose of 10 mg twice daily.
* Maximum dose: 20 mg twice daily.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS):**
* Ages 2 to less than 10 years: Initiate at 2.5 mg twice daily. Titrate by 2.5-5 mg per day every 7 days to a target dose of 5 mg twice daily. Maximum dose: 10 mg twice daily.
* Ages 10 years and older: Dosing is the same as adults.
* **Other Seizure Types:**
* Ages 2 to less than 10 years: Initiate at 2.5 mg twice daily. Titrate by 2.5-5 mg per day every 7 days to a target dose of 5 mg twice daily. Maximum dose: 10 mg twice daily.
* Ages 10 years and older: Dosing is the same as adults.
*Note: Dosing in children under 2 years of age is not well-established and should be approached with caution and individualized titration based on clinical response and tolerability.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider a lower starting dose and slower titration.
* **Renal Impairment:** Use with caution. Consider a lower starting dose and slower titration.
* **Concomitant Medications:** Dose reduction may be necessary when used with strong CYP3A4 inhibitors or other CNS depressants.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory depression.
* Severe hepatic insufficiency.
## Adverse Effects
Common: Somnolence, fatigue, constipation, decreased appetite, aggression, irritability, upper respiratory tract infection.
Serious: Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal ideation/behavior, paradoxical reactions (e.g., excitement, agitation), withdrawal symptoms upon discontinuation.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam levels; consider clobazam dose reduction.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease clobazam levels; consider clobazam dose increase.
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Additive CNS depression; use with extreme caution.
* **Phenobarbital, Primidone, Valproic Acid:** May increase clobazam levels.
## Monitoring
* Monitor for efficacy (seizure frequency reduction).
* Monitor for adverse effects, particularly somnolence, fatigue, and behavioral changes.
* Monitor for signs of respiratory depression, especially when used with other CNS depressants or in patients with underlying respiratory conditions.
* Monitor for signs of withdrawal if discontinuing therapy.
* Consider therapeutic drug monitoring if efficacy or toxicity is a concern, although specific target levels are not well-defined.
## Clinical Pearls
* Clobazam should be tapered slowly upon discontinuation to avoid withdrawal symptoms.
* Due to the risk of serious skin reactions, patients should be advised to discontinue clobazam and seek immediate medical attention if a rash develops.
* The risk of suicidal behavior and ideation has been observed with antiepileptic drugs, including clobazam. Monitor patients for any changes in mood or behavior.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.*
